107 related articles for article (PubMed ID: 18619723)
1. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Baumgartner C; Gleixner KV; Peter B; Ferenc V; Gruze A; Remsing Rix LL; Bennett KL; Samorapoompichit P; Lee FY; Pickl WF; Esterbauer H; Sillaber C; Superti-Furga G; Valent P
Exp Hematol; 2008 Oct; 36(10):1244-53. PubMed ID: 18619723
[TBL] [Abstract][Full Text] [Related]
2. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
[TBL] [Abstract][Full Text] [Related]
4. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
[TBL] [Abstract][Full Text] [Related]
8. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
[TBL] [Abstract][Full Text] [Related]
9. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
[TBL] [Abstract][Full Text] [Related]
10. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
[TBL] [Abstract][Full Text] [Related]
11. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
Jin Y; Chen Q; Lu Z; Chen B; Pan J
Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib].
Imagawa J; Harada Y; Yoshida T; Tarutani M; Kimura A; Matsumoto K; Morita K; Harada H
Rinsho Ketsueki; 2011 Jul; 52(7):546-50. PubMed ID: 21821988
[TBL] [Abstract][Full Text] [Related]
13. S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.
Lee JS; Lee NR; Kashif A; Yang SJ; Nam AR; Song IC; Gong SJ; Hong MH; Kim G; Seok PR; Lee MS; Sung KH; Kim IS
Front Immunol; 2020; 11():1258. PubMed ID: 32903598
[TBL] [Abstract][Full Text] [Related]
14. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
15. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
[TBL] [Abstract][Full Text] [Related]
16. All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line.
Robert C; Apàti A; Chomienne C; Papp B
Leuk Res; 2008 Feb; 32(2):343-6. PubMed ID: 17915318
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Griffin JH; Leung J; Bruner RJ; Caligiuri MA; Briesewitz R
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7830-5. PubMed ID: 12808148
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
19. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Verstovsek S; Giles FJ; Quintás-Cardama A; Manshouri T; Huynh L; Manley P; Cortes J; Tefferi A; Kantarjian H
Leuk Res; 2006 Dec; 30(12):1499-505. PubMed ID: 16682077
[TBL] [Abstract][Full Text] [Related]
20. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
Li B; Zhang G; Li C; He D; Li X; Zhang C; Tang F; Deng X; Lu J; Tang Y; Li R; Chen Z; Duan C
PLoS One; 2012; 7(4):e34912. PubMed ID: 22523564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
